NRD
BPMC

Nebula Research & Development’s Blueprint Medicines BPMC Stock Holding History

Nebula Research & Development’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,725
Closed -$418K – 963
2025
Q1 		$418K Sell
4,725
-3,034
-39% -$296K 0.04% 657
2024
Q4 		$677K Buy
7,759
+1,230
+19% +$113K 0.08% 439
2024
Q3 		$604K Buy
+6,529
New +$649K 0.07% 487

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nebula Research & Development's BPMC Position: Q2 2025 in Review

Nebula Research & Development sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 4,725 shares — an estimated $418K sold.

Nebula Research & Development first reported a position in BPMC in Q3 2024 and held it in 3 quarters. The position peaked at $677K in Q4 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Nebula Research & Development reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Nebula Research & Development sold 4,725 Blueprint Medicines shares in Q2 2025, an estimated $418K.
  • Nebula Research & Development first reported a position in Blueprint Medicines in Q3 2024 and held it in 3 quarters.
  • Nebula Research & Development's Blueprint Medicines position peaked at $677K in Q4 2024.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Nebula Research & Development's 13F filing for Q2 2025, filed 14 Aug 2025.